SPONSORED CONTENT
TIP: Treat the current delay in the 340B rebate model rollout as a strategic window to unify your procurement, finance, and compliance tech stacks, shifting from retrospective investigation to proactive program defensibility.
- The recent pause in the 340B rebate model rollout is not a reprieve; it is a critical maturity test for pharmacy leadership. Historically, many health systems have operated with fragmented workflows where finance, operations, and compliance functioned in silos. However, the pending transition to a rebate environment removes the buffers inherent in traditional upfront discount models. When your team is eventually required to purchase drugs at wholesale acquisition cost and defend eligibility within a narrow window, a “siloed” program becomes an operational liability. Every drug purchase will simultaneously become a financial, compliance, and operational decision.
- Pharmacy leaders must use this time wisely to achieve “data sovereignty.” This means building a unified tech stack that integrates EMR encounter data, pharmacy claims, purchasing records, and supply chain metrics into a single source of truth. By automating manual workflows and establishing continuous reconciliation now, you move your program from retrospective investigation to proactive assurance.
- Furthermore, this delay provides the opportunity to integrate 340B logic into daily procurement and shortage management. In a rebate model, a clinical substitution during a drug shortage can create immediate financial and regulatory exposure if not tracked in real-time. Organizations that treat this delay as preparation time – rather than waiting time – will be best positioned to maintain program integrity. By unifying your operational framework today, you ensure your 340B program remains a transparent, defensible, and sustainable financial stabilizer for the community you serve.
Sean Gilman is Director of Clinical Strategy at Bluesight. He can be reached at sean.gilman@bluesight.com
